Myasthenia gravis improvement in a patient receiving sunitinib for metastatic renal cell carcinoma
Jean S.Z. Lee, Rateb Samman, Oliver C. Cockerell, Kate Fife and Tim Eisen
Corresponding address:
Tim Eisen, PhD, FRCP, Department of Oncology, Box 193, Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK.
Email: tim.eisen@medschl.cam.ac.uk
We present a case of a 59-year-old gentleman with myasthenia gravis and metastatic renal cell carcinoma that resolved on sunitinib. The clear temporal relationship between the patient receiving sunitinib for renal cell carcinoma and the resolution of his myasthenia gravis suggests that the improvement was due either to a paraneoplastic condition responding to treatment of the underlying malignancy or to a direct effect of sunitinib.
Keywords
Renal cell carcinoma; kidney cancer; myasthenia gravis; sunitinib
Click here for printer-optimised version
